News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Novo Nordisk and Anthropic strike a partnership to leverage Claude and other AI models in the drug development process.
The company is still looking to bounce back after the beating it took in recent years.
Ascendis Pharma (ASND) share selloff on Tuesday after the termination of its collaboration agreement
Novo Nordisk Deepens AI Push Through Landmark Deal With Top AI Company
Sept 16 (Reuters) - Novo Nordisk has partnered with Anthropic to use the AI giant's Claude models to speed up discovery and development of new medicines, the companies said on Wednesday.
Novo will use Anthropic’s Claude Science in R&D to tackle scientific and drug discovery challenges, aiming to develop new medicines faster.
Investing.com -- In a welcome shift from recent AI doom reports, Novo Nordisk announced a major collaboration with Anthropic on Wednesday—highlighting artificial intelligence’s immense potential to save lives rather than threaten them.
Novo Nordisk (NYSE:NVO) has announced a collaboration with artificial intelligence company Anthropic to integrate AI models into its drug discovery, research and development, and software engineering activities. The partnership will combine Anthropic’s AI technology with Novo Nordisk’s scientific expertise to investigate how AI can support biological reasoning, address research problems and improve R&D workflows.
By Richa Naidu LONDON, Sept 16 (Reuters) - Consumer health company Haleon has achieved growing sales of products to counter side-effects of weight-loss drugs in the United States, the company said,
The Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company."
Novo said it will present 44 abstracts at the European Association for the Study of Diabetes symposium later this month.
Healthcare stocks were edging lower late Tuesday afternoon, with the NYSE Healthcare Index and the S
Healthcare stocks were edging down Tuesday afternoon, with the NYSE Healthcare Index fractionally lo
These stocks have been struggling lately, but they could be underrated buys in the long run.
A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.
A landmark trial just proved semaglutide can pull children as young as six below the obesity threshold, yet Wall Street shrugged and the real battle over who pays, who prescribes, and whether society is ready has barely begun.
Novo Nordisk Shares Fall as Wall Street Questions Its Next Growth Move
Eli Lilly and Company (NYSE:LLY) says its newly launched oral obesity drug Foundayo has captured more than 30% of new U.S. patients starting oral weight-loss medicines, a notable early gain against Novo Nordisk’s Wegovy pill. Reuters reports that Wegovy initially held roughly 90% of the oral market, making Lilly’s rapid share capture an important sign […]
Novo Nordisk A/S (NYSE:NVO)’s decision to rebrand its day-to-day identity as “Novo” and launch a cultural reset is primarily a strategic response to the company’s loss of momentum in the obesity-drug market, rather than a financial restructuring in itself. Reuters reports that the company is trying to regain competitiveness as pressure from Eli Lilly intensifies. […]
Healthcare stocks were falling pre-bell Tuesday, with the State Street Health Care Select Sector SPD
Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.
It’s legal to pay practising physicians to promote specific drugs — and thousands are doing so.
Ascendis Pharma (ASND) will regain exclusive rights to certain drug treatments for metabolic and car
Corbus Pharmaceuticals (NASDAQ:CRBP) reported top-line results from CANYON-1, a Phase 1b trial evaluating CRB-913, an oral, peripherally restricted CB1 inverse agonist for obesity. The 12-week, placebo-controlled study enrolled 254 patients across 15 U.S. sites, with participants having an average b
Novo Nordisk (CPSE:NOVO B) has rebranded to "Novo" as part of a shift toward a more consumer-focused healthcare identity. The group is introducing a new corporate culture intended to support its obesity and diabetes franchises in increasingly crowded markets. Management positions the rebrand as a move beyond traditional pharmaceuticals, with a broader focus on consumer-facing health solutions. The shift to the Novo identity reworks how the business presents itself to obesity drug users and...
Novo Nordisk (NYSE:NVO) has rebranded globally as "Novo" and introduced the "Lasting Health Starts Now" platform. The group is rolling out an updated corporate culture program called "The Novo Way" to align employees with the new identity. Management is positioning the refreshed brand and culture as a foundation for broader efforts to support improved health outcomes worldwide. The Novo rebrand and "Lasting Health Starts Now" push only capture part of the story investors need to weigh. Take...
Novo Nordisk dropped 'Nordisk' from its name, betting a culture reset can help it retake share from Eli Lilly.
The Danish drugmaker is shortening its name to Novo, but it will take more than a lean rebrand to win back Wall Street.
Novo Nordisk stock rallies as the company rebrands as Novo and introduces a new visual identity. Here’s what it means for NVO shares.